Eyenovia to Participate in Panel Presentation at OSN New York 2018
September 19, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 18, 2018 07:30 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference
August 21, 2018 07:30 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Reports Second Quarter 2018 Financial Results
August 14, 2018 06:30 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
August 13, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Announces Conference Call and Webcast for Second Quarter 2018 Financial Results
July 31, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs
July 09, 2018 07:30 ET
|
Eyenovia, Inc.
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference
June 11, 2018 07:30 ET
|
Eyenovia, Inc.
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Delivery
June 05, 2018 07:30 ET
|
Eyenovia, Inc.
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented...
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study
May 09, 2018 06:30 ET
|
Eyenovia, Inc.
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print...